Affordable Access

deepdyve-link
Publisher Website

Mevalonate metabolism in cancer

Authors
  • Gruenbacher, Georg
  • Thurnher, Martin1, 2, 3, 4
  • 1 Cell Therapy Unit
  • 2 Department of Urology
  • 3 Innsbruck Medical University and Oncotyrol
  • 4 K1 Center for Personalized Cancer Medicine
Type
Published Article
Journal
Cancer Letters
Publisher
Elsevier
Publication Date
Jan 01, 2014
Accepted Date
Jan 19, 2014
Identifiers
DOI: 10.1016/j.canlet.2014.01.013
Source
Elsevier
Keywords
License
Unknown

Abstract

Cancer cells are characterized by sustained proliferative signaling, insensitivity to growth suppressors and resistance to apoptosis as well as by replicative immortality, the capacity to induce angiogenesis and to perform invasive growth. Additional hallmarks of cancer cells include the reprogramming of energy metabolism as well as the ability to evade immune surveillance. The current review focuses on the metabolic reprogramming of cancer cells and on the immune system’s capacity to detect such changes in cancer cell metabolism. Specifically, we focus on mevalonate metabolism, which is a target for drug and immune based cancer treatment.

Report this publication

Statistics

Seen <100 times